Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PX-866 + Sorafenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PX-866 | Sonolisib|PX866 | PI3K Inhibitor (Pan) 38 | Sonolisib (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839). | |
Sorafenib | Nexavar | BAY 43-9006 | CSF1R Inhibitor 25 FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 16 RET Inhibitor 39 VEGFR2 Inhibitor 35 | Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | PX-866 + Sorafenib | Preclinical | Actionable | In a preclinical study, treatment with the combination of Stivarga (regorafenib) PK-866 resulted in increased cell death in a variety of solid tumor cell lines in culture (PMID: 23877009). | 23877009 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|